Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furosemide with or without acetazolamide in critically ill ICU patients
ACTRN12623000624684Phase 2Completed
- Sponsor
- Austin Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in critical illness comparing Furosemide + acetazolamide with Furosemide (2 arms). Primary endpoint: Urinary output after diuretic administration. Started May 2023; status: completed.
02
Drugs
furosemideacetazolamide
03
Conditions
critical illness
Beyond the preview
Go deeper on ACTRN12623000624684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000624684.